Similar articles

• Antithrombotic therapy to support primary PCI.

  Morrow DA. Morrow DA. N Engl J Med. 2008 May 22;358(21):2280-2. doi: 10.1056/NEJMe0802383. N Engl J Med. 2008. PMID: 18499573 No abstract available.
• Platelet resistance - much known and much more unknown.

  Dieter RS, Lopez JJ, Nanjundappa A. Dieter RS, et al. J Invasive Cardiol. 2011 Jan;23(1):14. J Invasive Cardiol. 2011. PMID: 21183764 No abstract available.
• The future of an illusion.

  Bittl JA. Bittl JA. J Am Coll Cardiol. 2006 Jun 20;47(12):2380-3. doi: 10.1016/j.jacc.2006.03.029. J Am Coll Cardiol. 2006. PMID: 16781362 No abstract available.
• Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists.

  Harker LA, Hanson SR, Kelly AB. Harker LA, et al. Thromb Haemost. 1995 Jul;74(1):464-72. Thromb Haemost. 1995. PMID: 8578508 Review. No abstract available.
• Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.

  Campbell KR, Mahaffey KW, Lewis BE, Weitz JI, Berkowitz SD, Ohman EM, Califf RM. Campbell KR, et al. J Invasive Cardiol. 2000 Dec;12 Suppl F:14F-9. J Invasive Cardiol. 2000. PMID: 11156729 Review. No abstract available.